Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

Sajeve Samuel Thomas,Gino K. In,Bernard Doger,Simon Haefliger,Juan Martin-Liberal,Zelanna Goldberg,Alex Cacovean,Rana Fiaz,Guang Chen,Madan Jagasia,Friedrich Graf Finckenstein,Maria Fardis,Antonio Jimeno

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

2021

Sajeve Samuel Thomas
Gino K. In
Bernard Doger
Simon Haefliger
Juan Martin-Liberal
Zelanna Goldberg
Alex Cacovean
Rana Fiaz
Guang Chen
Madan Jagasia
Friedrich Graf Finckenstein
Maria Fardis
Antonio Jimeno

9537Background: Tumor infiltrating lymphocyte (TIL) cell therapy has demonstrated safety and efficacy in advanced melanoma, both in the pre-immune checkpoint inhibitor (ICI) setting (Goff, JCO 2016...

Keywords:

autologous tumor
Medicine
Pembrolizumab
advanced melanoma
Lymphocyte
therapy naive
Cancer research
Tumor-infiltrating lymphocytes
Cell therapy
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations